Article Review: Improving The Permeability of BCS Class II, III, and IV Drugs Using the Co-Amorph Method
Main Article Content
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Aulton, M.E., dan Kelvin, M.G.T. 2018. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th Edition. UK: Elsevier.
Chavan RB, Thipparaboina R, Kumar D, Shastri NR. 2016. Co amorphous systems: A product development perspective. Int J Pharm. 515(1-2):403-415.
Chen X, Li D, Zhang H, Duan Y, Huang Y. 2021. Co-amorphous systems of sinomenine with nonsteroidal anti-inflammatory drugs: A strategy for solubility improvement, sustained release, and drug combination therapy against rheumatoid arthritis. Int J Pharm. 606:120894.
China Pharmaceutical University. 2013. A simvastatin-gliclazide co-amorphous compound. Available from: https://patents.google.com/patent/CN103360357A/en
China Pharmaceutical University. 2013. Carvedilol-asccharin amorphous compound. Available from: https://patents.google.com/patent/CN103467363A/en
China Pharmaceutical University. 2013. Irbesartan and repaglinide co-amorphous substance. Available from: https://patents.google.com/patent/CN103497178A/en?oq=CN103497178A
Dengale SJ, Grohganz H, Rades T, Löbmann K. 2016. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 100:116-25.
Hatanaka, Y., Uchiyama, H., Kadota, K., & Tozuka, Y. 2021. Improved solubility and permeability of both nifedipine and ketoconazole based on coamorphous formation with simultaneous dissolution behavior. Journal of Drug Delivery Science and Technology. 65: 102715.
Hebei Medical University. 2015. Azelnidipine-maleic acid co-amorphous substance and preparation method. Available from: https://patents.google.com/patent/CN104693181A/en
Hirakawa, Y., Hiroshi Ueda, Tetsuya Miyano, Noriho Kamiya, Masahiro Goto. 2019. New insight into transdermal drug delivery with supersaturated formulation based on co-amorphous system. International Journal of Pharmaceutics. 569: 118582.
Jana, S., dan Subrata, J. 2017. Particulate Technology for Delivery of Therapeutics. Singapore: Springer.
Jensen KT, Larsen FH, Löbmann K, Rades T, Grohganz H. 2016. Influence of variation in molar ratio on co-amorphous drug-amino acid systems. Eur J Pharm Biopharm. 107:32-9.
Karagianni, A., Kachrimanis, K., Nikolakakis, I. 2018. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: composition, preparation, characterization and formulations for oral delivery. Pharmaceutics. 10(3):98.
Korhonen, Ossi., Pajula, K., Laitinen, R. 2016. Rational excipient selection for co-amorphous formulations. Expert Opinion on Drug Delivery. 14(4):551-569.
Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. 2013. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 453(1):65-79.
Löbmann K, Laitinen R, Grohganz H, Strachan C, Rades T, Gordon KC. 2013. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int J Pharm. 453(1):80-7.
MIMS. 2022. MIMS. Available from: https://www.mims.com/indonesia
Mizoguchi R, Waraya H, Hirakura Y. 2019. Application of co-amorphous technology for improving the physicochemical properties of amorphous formulations. Mol Pharm. 16(5):2142-2152.
Prajapati, B., Indrani Maji, Rahul Kumar, Devendrasingh Tomar, Dharmendra Kumar Khatri, Jitender Madan, Pankaj Kumar Singh. 2022. Strategy to counteract the pyrazinamide induced hepatotoxicity by developing naringin based co-amorphous system with supplementary benefits. Journal of Drug Delivery Science and Technology. 69: 103181.
Ruponen M, Kettunen K, Santiago Pires M, Laitinen R. 2021. Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs. Pharmaceutics. 13(2):171.
Ruponen, M., Henna, R., dan Riikka, L. 2020. Dissolution and permeability properties of co-amorphous formulations of hydrochlorothiazide. Journal of Pharmaceutical Sciences. 109(7).
Setyawan, D., dan Diajeng, P. P. 2020. Strategi Peningkatan Kelarutan Bahan Aktif Farmasi. Surabaya: Airlangga University Press.
Sormunen H, Ruponen M, Laitinen R. 2019. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer. Int J Pharm. 570:118653.
Teja A, Musmade PB, Khade AB, Dengale SJ. 2015. Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of talinolol with naringin: Solid state characterization, in-vivo in-situ evaluation. Eur J Pharm Sci. 78:234-44.
Tianjin Institute of Pharmaceutical Research Co Ltd. 2013. Co-amorphous system and preparation method. Available from: https://patents.google.com/patent/CN104415042A/en?oq=CN104415042A
Uppala, S., Sai Krishna Anand Vullendula, Dani Lakshman Yarlagadda, Swapnil Jayant Dengale. 2022. Exploring the utility of co-amorphous materials to concurrently improve the solubility and permeability of fexofenadine. Journal of Drug Delivery Science and Technology. 72: 103431.
Wang, R., Jiawei Han, Ai Jiang, Rong Huang, Tingming Fu, Lingchong Wang, Qin Zheng, Wen Li, Junsong Li. 2019. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. International Journal of Pharmaceutics. 561: 9-18,
Wiergowska G, Ludowicz D, Wdowiak K, Miklaszewski A, Lewandowska K, Cielecka-Piontek J. 2021. Combinations of freeze-dried amorphous vardenafil hydrochloride with saccharides as a way to enhance dissolution rate and permeability. Pharmaceuticals. 14(5):453.
Wuhan Yuan Zhu Pharmaceutical Technology Co Ltd. 2014. Baicalein-caffeine amorphous compound. Available from: https://patents.google.com/patent/CN103923049A/en?oq=CN103923049A
Yu D, Kan Z, Shan F, Zang J, Zhou J. 2020. Triple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: enhancing water-solubility, permeability, and inhibiting cytochrome p450 isozymes. Mol Pharm. 17(12):4443-4462.